Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes

by Heeseung Jo, Venkatesh Pilla Reddy, Joanna Parkinson, David W. Boulton, Weifeng Tang
Published 2021-02-01

Use systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans

by Yasong eLu, Steven C Griffen, David W Boulton, Tarek A Leil
Published 2014-12-01

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

by Pia S. Pollack, Kristina D. Chadwick, David M. Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal, David W. Boulton
Published 2017-09-01

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

by Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J. Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland
Published 2020-04-01

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

by Gabriel Helmlinger, Victor Sokolov, Kirill Peskov, Karen M. Hallow, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Tatiana Yakovleva, Ivan Azarov, Daniel Kaschek, Artem Dolgun, Henning Schmidt, David W. Boulton, Robert C. Penland
Published 2019-06-01

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights fr...

by Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman
Published 2019-10-01